我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去）

Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
* E, ^3 `% ~  S% m! |NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
! s, V. R* B0 Y& b! J+ Author Affiliations
: e0 @$ E3 R! \" S3 D* V$ e) S8 o, z
2 |9 ]* ~$ q$ B- R/ _( T- F. K1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
5 ?8 O* J' Z' Y, V! V2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
6 I; t% I0 w+ s0 l- a2 M3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
+ P2 W5 z5 M/ W* r. w, m( B4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
7Kinki University School of Medicine, Osaka 589-8511, Japan
: X  S3 l; A( X0 y: u& g2 K% w8Izumi Municipal Hospital, Osaka 594-0071, Japan
0 F* Y0 J; P9 i4 r* r( K9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
9 ~& q' I& U. U* n
+ l9 S' t% `# G/ g* M

S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
+ k4 u+ ~% S; x! E, a
8 C! t6 ?' e) h* |. k; FAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato

Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  

( r" V& k: E" e- i3 k! VPublished online on: Thursday, December 1, 2011
# y2 S6 E) f& ]1 s; w; X6 d1 X
Doi: 10.3892/ol.2011.507
+ H$ n. a( e2 e; V0 R9 a( `
Pages: 405-410
  K# w' f+ }$ f$ m
) t, q) B9 @& p# O, [' c1 R# J! [' xAbstract:
- r1 M$ O' A- Q* G7 gS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
4 b7 x0 k  G7 @+ h7 C# X: }

Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
- |% S- u3 |  A& f( b7 Y+ Author Affiliations
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
2Department of Thoracic Surgery, Kyoto University, Kyoto
$ }) p* E0 d7 b0 x$ }3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
) G0 f  d/ V1 H: x! c( k$ D+ |! |( u&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
Received September 3, 2010.
, C' Y0 j  P8 eRevision received November 11, 2010.
  z" y: Q7 t) E' t. F4 LAccepted November 17, 2010.
" E  T; [$ C$ h: _4 u/ l7 \Abstract
9 o& X3 r& C2 D1 d. ?Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
Patients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
" g& A# J6 n( W8 Z! k) u/ WResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.

一直关注老马的帖子，前方的指明灯。祝福你爸好疗效

一直得到老马帮助，祝福老马爸爸

26日吃了12片地米（0.75mg一片），27日吃了22片地米（0.75mg 一片），28日吃了12片地米（0.75mg一片），都分二次吃。
" F- \3 k, O9 K- A. G) [1 \今天为止没有任何反应，每天吃VC,VB2，还有漱口水，就怕口腔溃疡。

副作用如何，单药反应很小吧？
2 _, T& u) f' i3 ^# n

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
http://clinicaltrials.gov/ct2/show/NCT01523587

- I. f" h! _. F3 l7 ?4 P5 E4 nBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
6 Y+ S2 X7 Q* g+ ?; W4 _http://clinicaltrials.gov/ct2/show/NCT01156545

; @2 o6 W. u# h1 f- P
* }% R( ^- X( q& n" u8 B* B1 R从4月24日开始到4月28日，打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
至今为止，未出现化疗副作用。

老马 发表于 2012-4-29 20:53

# w9 G6 f1 I! _                               
登录/注册后可看大图

从4月24日开始到4月28日，打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
至今为止，未出 ...

% t8 Z- M% {( R$ c$ }) _没有副作用是第一追求，效果显著是第二追求。
! N* ]8 ?5 x! t  a不错。